Positive News SentimentPositive NewsNASDAQ:STIM Neuronetics (STIM) Stock Price, News & Analysis $2.22 -0.12 (-4.91%) As of 10:55 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Neuronetics Stock (NASDAQ:STIM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Neuronetics alerts:Sign Up Key Stats Today's Range$2.27▼$2.3850-Day Range$1.73▼$3.3052-Week Range$0.80▼$3.44Volume136,861 shsAverage Volume2.12 million shsMarket Capitalization$169.47 millionP/E RatioN/ADividend YieldN/APrice Target$4.67Consensus RatingModerate Buy Company Overview Neuronetics, Inc. is a medical technology company focused on developing and commercializing noninvasive treatments for patients with psychiatric and neurological disorders. The company’s flagship product is NeuroStar Advanced Therapy, a transcranial magnetic stimulation (TMS) system designed to deliver personalized, outpatient treatment for major depressive disorder and obsessive-compulsive disorder. NeuroStar systems use magnetic pulses to stimulate targeted areas of the brain without surgery or anesthesia. Neuronetics supports providers with treatment-planning tools, clinical education, practice-development services and patient-acquisition programs intended to help expand access to TMS therapy. The company has also pursued additional applications for its technology, including treatments related to smoking cessation. Founded in 2003 and headquartered in Malvern, Pennsylvania, Neuronetics primarily serves behavioral healthcare providers and patients in the United States, with activities extending to select international markets. The company has been led by Chief Executive Officer Keith Sullivan, who joined Neuronetics in 2019 and became CEO in 2020.AI Generated. May Contain Errors. Read More Neuronetics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks88th Percentile Overall ScoreSTIM MarketRank™: Neuronetics scored higher than 88% of companies evaluated by MarketBeat, and ranked 47th out of 891 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingModerate Buy Consensus RatingNeuronetics has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on no strong buy ratings, 4 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialNeuronetics has a consensus price target of $4.67, representing about 99.5% upside from its current price of $2.34.Amount of Analyst CoverageNeuronetics has only been the subject of 4 research reports in the past 90 days.Read more about Neuronetics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Neuronetics are expected to grow in the coming year, from ($0.33) to ($0.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Neuronetics is -5.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Neuronetics is -5.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNeuronetics has a P/B Ratio of 6.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Neuronetics' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted8.90% of the float of Neuronetics has been sold short.Short Interest Ratio / Days to CoverNeuronetics has a short interest ratio ("days to cover") of 3.74, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Neuronetics has recently decreased by 6.87%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNeuronetics does not currently pay a dividend.Dividend GrowthNeuronetics does not have a long track record of dividend growth. News and Social Media3.6 / 5News SentimentN/A News SentimentNeuronetics has a news sentiment score of 1.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Neuronetics this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for STIM on MarketBeat in the last 30 days. This is a decrease of -91% compared to the previous 30 days.MarketBeat Follows3 people have added Neuronetics to their MarketBeat watchlist in the last 30 days. Company Ownership3.8 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $44,240.00 in company stock, which represents 0.0248% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Neuronetics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $44,240.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders8.40% of the stock of Neuronetics is held by insiders.Percentage Held by Institutions53.59% of the stock of Neuronetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Neuronetics' insider trading history. Receive STIM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neuronetics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. STIM Stock News HeadlinesB Riley Securities initiates coverage of Neuronetics at buySeptember 12, 2026 | msn.comB. Riley Initiates Neuronetics at Buy With $5 Price TargetSeptember 11, 2026 | marketscreener.comMHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.October 1 at 1:00 AM | Stansberry Research (Ad)NeuroStar Advances Practice Innovation with First-Ever TMS Integration with an EHR/EMR SystemSeptember 8, 2026 | globenewswire.comNeuronetics (STIM) Q2 2026 Earnings Call TranscriptAugust 18, 2026 | finance.yahoo.comNeuronetics, Inc. (STIM) Q2 FY2026 earnings call transcriptAugust 12, 2026 | finance.yahoo.comNeuronetics Inc (STIM) (Q2 2026) Earnings Call Highlights: Revenue Growth and Margin Expansion ...August 12, 2026 | finance.yahoo.comNeuronetics Reports Second Quarter 2026 Financial and Operating ResultsAugust 11, 2026 | markets.businessinsider.comSee More Headlines STIM Stock Analysis - Frequently Asked Questions How have STIM shares performed this year? Neuronetics' stock was trading at $1.38 at the beginning of the year. Since then, STIM stock has increased by 69.5% and is now trading at $2.3390. How were Neuronetics' earnings last quarter? Neuronetics, Inc. (NASDAQ:STIM) announced its earnings results on Tuesday, August, 11th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.07. The firm earned $41.57 million during the quarter, compared to analysts' expectations of $40.17 million. Neuronetics had a negative net margin of 19.62% and a negative trailing twelve-month return on equity of 125.11%. Read the conference call transcript. When did Neuronetics IPO? Neuronetics (STIM) raised $82 million in an IPO on Thursday, June 28th 2018. The company issued 5,500,000 shares at a price of $14.00-$16.00 per share. Piper Jaffray and William Blair acted as the underwriters for the IPO and Canaccord Genuity, BTIG and JMP Securities were co-managers. How do I buy shares of Neuronetics? Shares of STIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Neuronetics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Neuronetics investors own include Gilead Sciences (GILD), SCYNEXIS (SCYX), Pfizer (PFE), GE Aerospace (GE), Intel (INTC), Bank of America (BAC) and Nokia (NOK). Company Calendar Last Earnings8/11/2026Today10/01/2026Next Earnings (Estimated)11/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 STIM's financial health is in the Green zone, according to TradeSmith. STIM has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNASDAQ:STIM CIK1227636 Webwww.neurostar.com Phone(610) 640-4202Fax610-640-4206Employees658Year Founded2003Price Target and Rating Average Price Target for Neuronetics$4.67 High Price Target$6.00 Low Price Target$3.00 Potential Upside/Downside+105.1%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($0.44) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$39 million Net Margins-19.62% Pretax Margin-19.89% Return on Equity-125.11% Return on Assets-22.15% Debt Debt-to-Equity Ratio2.84 Current Ratio1.88 Quick Ratio1.69 Sales & Book Value Annual Sales$149.16 million Price / Sales1.16 Cash FlowN/A Price / Cash FlowN/A Book Value$0.38 per share Price / Book5.99Miscellaneous Outstanding Shares76,200,000Free Float69,796,000Market Cap$173.36 million OptionableOptionable Beta1.16 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:STIM) was last updated on 10/1/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neuronetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neuronetics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
